Weekly Insulin: A Step Forward, but What’s Next for Indian Diabetes Care?

The introduction of Novo Nordisk’s Awiqli, a once-a-week basal insulin, marks a significant development in India’s diabetes treatment. With an estimated 101 million people living with diabetes and another 136 million at risk of developing the condition, India remains one of the world’s largest diabetes hotspots.

Awiqli is part of a broader push by pharmaceutical companies to expand their product portfolios and tap into emerging markets. Novo Nordisk has already launched this product in over a dozen countries worldwide. However, its introduction in India cannot be overstated, given the complexities and challenges surrounding insulin therapy in the country.

For doctors, Awiqli offers an opportunity to provide patients with a more manageable treatment regimen. Insulin injections can be daunting for many, particularly those living in rural areas or facing socio-economic barriers to healthcare access. The fear of daily injections has been cited as one of the primary reasons why patients delay initiating insulin therapy by seven to nine years on average.

The introduction of Awiqli may also help alleviate some of the strain on India’s already overburdened healthcare system. By providing a less frequent dosing schedule, this new option could simplify treatment protocols and reduce the burden on patients. However, it does not directly address concerns about affordability and accessibility that are prevalent in low- and middle-income countries.

In India, oral medications are often prescribed as a first line of defense against diabetes. The introduction of Awiqli raises questions about the role of insulin therapy in Type 2 diabetes management. While not all Type 2 patients require insulin, those who do may benefit from more flexible treatment options like this new product.

The success of Awiqli will depend on its ability to reach and benefit those who need it most – namely, patients from underserved communities and rural areas where access to quality care remains limited. To achieve this, healthcare providers and policymakers must monitor the adoption and impact of Awiqli in India, ensuring that it is integrated into existing treatment protocols and support systems.

Careful consideration must be given to factors such as affordability, availability, and patient education. Efforts should also be made to address systemic barriers and foster greater collaboration between healthcare providers, pharmaceutical companies, and policymakers. By doing so, India can take a significant stride towards providing more comprehensive diabetes care for all its citizens.

As the global diabetes community continues to evolve and adapt to emerging challenges, innovations like Awiqli offer a glimmer of hope for patients worldwide. In India specifically, this new product represents an opportunity to rethink treatment approaches and prioritize patient-centered care. However, as we move forward, it’s essential to remain vigilant about the needs of our most vulnerable populations and work towards creating a more equitable and accessible healthcare landscape – one that truly serves all those affected by diabetes.